

## Vitamin D Deficiency May Explain the Possible Link Between Gout and Erectile Dysfunction

To the Editor:

Two articles recently published in the *Journal of Rheumatology* have explored a possible relationship between gout and erectile dysfunction. In the cross-sectional study conducted by Schlesinger, *et al*<sup>1</sup>, a significantly greater proportion of patients with gout (63.76%) had erectile dysfunction (ED) versus patients without gout (60.51%). The association remained significant after adjustment for age, hypertension, diabetes, and obesity (adjusted OR 2.92, 95% CI 1.41–6.06). Chen, *et al*<sup>2</sup> reported similar results using a nationwide cohort study design in Taiwan. The gout cohort exhibited a 1.21-fold adjusted HR of subsequent ED development compared with the non-gout cohort (95% CI 1.03–1.44). This causal study also demonstrated that patients with a different number of comorbidities exhibited a dose-response effect of ED development compared to the non-gout participants with no comorbidity.

As numerous investigators have noted, the main mechanisms underlying the association between ED and gout include endothelial dysfunction, oxidative stress, and inflammation induced by elevated serum uric acid, and the comorbidities associated with gout that are connected with similar risks of vascular diseases<sup>3</sup>. In addition to this, gout *per se* is a source of stress for affected individuals; this would directly cause the development of ED.

Another explanation of the link between ED and gout might be vitamin D deficiency (VDD). Since 1993, attention has focused on the association between 1,25(OH)<sub>2</sub>D<sub>3</sub> and elevated serum uric acid. It was reported that uric acid could suppress the synthesis of 1,25(OH)<sub>2</sub>D<sub>3</sub> in patients with renal failure and hyperuricemia<sup>4</sup>, and the serum active vitamin D levels were inversely related to the serum uric acid level<sup>5</sup>. In patients with gout, the serum 1,25(OH)<sub>2</sub>D<sub>3</sub> concentration but not 25(OH)D<sub>3</sub> was significantly lower than that in the healthy male subjects<sup>6</sup>. Based upon these observations, Chen, *et al*<sup>7</sup> found that hyperuricemia in an experimental rat model could suppress 1- $\alpha$  hydroxylase through nuclear factor- $\kappa$ B signaling, which leads to lower serum 1,25(OH)<sub>2</sub>D<sub>3</sub>.

Does VDD contribute to ED? Sorenson and colleagues concluded that VDD contributes to ED because VDD is one of several factors that associates with increased cardiovascular disease (CVD)<sup>8</sup>. CVD and ED share many of the same risk factors, and VDD is closely associated with both disorders. To test this hypothesis, Barassi, *et al*<sup>9</sup> evaluated the status of serum vitamin D in a group of patients with arteriogenic, borderline, or nonarteriogenic ED. Their study shows that a significant proportion of patients with ED have VDD and that this condition is more frequent in patients with the arteriogenic etiology<sup>9</sup>. However, to our knowledge no interventional studies have assessed the beneficial effect of vitamin D supplementation in male subjects with ED and/or gout.

We emphasize the pivotal role of VDD in the pathogenesis of gout and ED. It would have been interesting if Schlesinger and Chen and their colleagues had measured the concentration of serum 1,25(OH)<sub>2</sub>D<sub>3</sub> and 25(OH)D<sub>3</sub>. If proven by future studies that VDD is a risk factor for ED and gout, then men with gout and/or ED should be routinely screened for VDD. For the patients with low levels of vitamin D, replacement therapy to raise it to above 30 ng/ml is suggested.

ZHENG-TAO LV, MD, Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; AN-MIN CHEN, PhD, Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095#, Jiefang Road, Qiaokou District, Wuhan, Hubei 430030, China. Address correspondence to A.M. Chen; e-mail: anminchen@hust.edu.cn

### REFERENCES

1. Schlesinger N, Radvanski DC, Cheng JQ, Kostis JB. Erectile dysfunction is common among patients with gout. *J Rheumatol* 2015;42:1893-7.
2. Chen YF, Lin HH, Lu CC, Hung CT, Lee MH, Hsu CY, et al. Gout and a subsequent increased risk of erectile dysfunction in men aged 64 and under: a nationwide cohort study in Taiwan. *J Rheumatol* 2015;42:1898-905.
3. Edwards NL. The role of hyperuricemia in vascular disorders. *Curr Opin Rheumatol* 2009;21:132-7.
4. Vanholder R, Patel S, Hsu CH. Effect of uric acid on plasma levels of 1,25(OH)<sub>2</sub>D in renal failure. *J Am Soc Nephrol* 1993;4:1035-8.
5. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. *Am J Hypertens* 1995;8:894-901.
6. Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Yamakita J, Higashino K. Decreased serum concentrations of 1,25(OH)<sub>2</sub>-vitamin D<sub>3</sub> in patients with gout. *Adv Exp Med Biol* 1998;431:57-60.
7. Chen W, Roncal-Jimenez C, Lanasma M, Gerard S, Chonchol M, Johnson RJ, et al. Uric acid suppresses 1 alpha hydroxylase in vitro and in vivo. *Metabolism* 2014;63:150-60.
8. Sorenson M, Grant WB. Does vitamin D deficiency contribute to erectile dysfunction? *Dermatoendocrinol* 2012;4:128-36.
9. Barassi A, Pezzilli R, Colpi GM, Corsi Romanelli MM, Melzi d'Eril GV. Vitamin D and erectile dysfunction. *J Sex Med* 2014;11:2792-800.

*J Rheumatol* 2016;43:8; doi:10.3899/jrheum.160056